This is a working overview of research chemical, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-03-17 and is reviewed periodically as new material appears.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
=== Decreased lactose content === During the fermentation process, bacteria and yeast break lactose down into glucose and galactose. As a result of the fermentation, lactose levels are decreased by 20–30% with respect to the initial lactose levels present in the milk. One study found that when people with lactose intolerance consumed the same amount of lactose in milk, kefir or yogurt products, the latter two showed significantly reduced symptoms of lactose intolerance during the first 8 hours after consumption. This result suggests that yogurt and kefir might be suitable for people with lactose intolerance. However, the long-term impact of kefir consumption on lactose intolerance has not been studied. It has also been shown that fermented milk products have a slower transit time than milk, which may further improve lactose digestion.
Radio (the general technology of communicating using radio waves) has many practical applications, which include broadcasting, voice communication, data communication, radar, radiolocation, medical treatments, and remote control.
primer A short, single-stranded oligonucleotide, typically 5–100 bases in length, which "primes" or initiates nucleic acid synthesis by hybridizing to a complementary sequence on a template strand and thereby providing an existing 3'-end from which a polymerase can extend the new strand. Natural systems exclusively use RNA primers to initiate DNA replication and some forms of prokaryotic transcription, whereas the in vitro syntheses performed in many laboratory techniques such as PCR often use DNA primers. In modern laboratories, primers are carefully designed, often in "forward" and "reverse" pairs, to complement specific and unique sequences in target DNA molecules, with consideration given to their melting and annealing temperatures, and then purchased from commercial suppliers which create oligonucleotides on demand by de novo synthesis.
Tolkien was English, and thought of himself as such. His immediate paternal ancestors were middle-class craftsmen who made and sold clocks, watches and pianos in London and Birmingham. The Tolkien family originated in the East Prussian town of Kreuzburg near Königsberg, which had been founded during the medieval German eastward expansion, where his earliest-known paternal ancestor, Michel Tolkien, was born around 1620. In 1792 John Benjamin Tolkien and William Gravell took over the Erdley Norton manufacture in London, which from then on sold clocks and watches under the name Gravell & Tolkien. John Benjamin's brother Daniel Gottlieb Tolkien obtained British citizenship in 1794, but John Benjamin Tolkien apparently never became a British citizen. Other German relatives joined the two brothers in London. Several people with the surname Tolkien or similar spelling, some of them members of the same family as J. R. R. Tolkien, live in northern Germany, but most of them are descendants of people who were evacuated from East Prussia in 1945, at the end of the Second World War. According to Ryszard Derdziński, the surname Tolkien is of Low Prussian origin and probably means "son/descendant of Tolk". Tolkien mistakenly believed his surname derived from the German word tollkühn, meaning "foolhardy", and jokingly inserted himself as a "cameo" into The Notion Club Papers under the literally translated name Rashbold. However, Derdziński has demonstrated this to be a false etymology. Another suspected origin is the East Prussian village of Tołkiny. While J. R. R.
Sources: en.wikipedia.org
=== Solid interfaces === Nano-particles can self-assemble on solid surfaces after external forces (like magnetic and electric) are applied. Templates made of microstructures, like carbon nanotubes or block polymers, can also be used to assist in self-assembly. They cause directed self-assembly (DSA), in which active sites are embedded to selectively induce nanoparticle deposition. Such templates are objects onto which different particles can be arranged into a structure with a morphology similar to that of the template. Carbon nanotubes (microstructures), single molecules, or block copolymers are common templates. Nanoparticles are often shown to self-assemble within distances of nanometers and micrometers, but block copolymer templates can be used to form well-defined self-assemblies over macroscopic distances. By incorporating active sites to the surfaces of nanotubes and polymers, the functionalization of these templates can be transformed to favor self-assembly of specified nanoparticles.
Enzymatic hydrolysis similar to the body's natural digestive process provides the most efficient breakdown of the proteins into smaller fractions termed peptides which can then be separated from the oil and non-digested proteins during liquid phase processing. Subsequent steps of solids and oil removal through various mechanical separation techniques are required to create a final fish protein fraction with acceptable organoleptic properties for use in human food. Minimization of odor through the elimination of fat and oil from the protein fraction, as well as separating out the lowest molecular weight protein fractions from the larger fractions all serve to create a refined fish protein. Some processes utilize solvents to extract the fat but these can result in dangerous handling and potential residual issues. The final step in producing the product is typically spray drying, which involves atomizing the liquid protein in a hot air chamber resulting in rapid evaporation of the water and a fine powder falling to the bottom of the chamber for removal.
==== Resistance exercise and muscle atrophy ==== Resistance exercise is exercising a muscle or muscle group against external resistance (see strength training). Studies have found that: a) mice feeding on a high fat or normal diet and given the resistance exercise of repeatedly climbing up a 1 meter ladder for 40 minutes had higher levels of α-ketoglutarate in their blood and seven muscles than non-exercising mice feeding respectively on the high fat or normal diet; b) mice conducting ladder climbing for several weeks and eating a high fat diet developed lower fat tissue masses and higher lean tissue masses than non-exercising mice on this diet; c) mice not in exercise training fed α-ketoglutarate likewise developed lower fat tissue and higher lean tissue masses than α-ketoglutarate-unfed, non-exercising mice; d) OXGR1 was strongly expressed in the mouse adrenal gland inner medullas and either resistance training or oral α-ketoglutarate increased this tissue's levels of the mRNA that is responsible for the synthesis of OXGR1; e) α-ketoglutarate stimulated chromaffin cells isolated from mouse adrenal glands to release epinephrine but reduction of these cells' OXGR1 levels by small interfering RNA reduced this response; f) α-ketoglutarate increased the blood serum levels of epinephrine in mice expressing OXGR1 but not in Oxgr1 gene knockout mice (i.e., mice lacking the OXGR1 gene and protein); g) mice on the high fat diet challenged with α-ketoglutarate increased their blood serum levels of epinephrine and developed lower fat tissue masses and higher lean tissue masses but neither OXGR1 gene knockout mice nor mice that had only their adrenal glands' OXGR1 gene knocked out showed these responses; and h) OXGR1 gene knockout mice fed the high fat diet developed muscle protein degradation, muscle atrophy (i.e., wasting), and falls in body weight whereas control mice did not show these fat diet-induced changes. These findings indicate that in mice resistance exercise increases muscle production as well as serum levels of α-ketoglutarate which in turn suppresses diet-induced obesity (i.e., low body fat and high lean body masses) at least in part by stimulating the OXGR1 on adrenal gland chromaffin cells to release epinephrine. Additional mechanisms include inhibition of hepatic gluconeogenesis via serpina1e signaling (reducing hyperglycemia) and activation of the PHD3/ADRB2 pathway in muscle cells. Supplementation studies have shown that oral α-ketoglutarate increases serum levels of α-ketoglutarate, suppresses obesity and improves glucose tolerance in mice. See § Glucose tolerance below.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.